Krystal Biotech Inc is a biotechnology company focused on developing innovative gene therapies to treat debilitating skin and rare diseases. The company harnesses its proprietary, skin-targeted gene delivery platform to create treatments aimed at addressing the underlying genetic causes of these conditions. By advancing its pipeline of product candidates, Krystal Biotech seeks to provide transformative therapies that can improve the quality of life for patients affected by various skin disorders and other genetic conditions. The company's commitment to research and development ensures a strong focus on scientific excellence and innovative solutions in the field of gene therapy. Read More
Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.
Commodity prices regularly swing 25-30% or more in any given year. When this happens, the financial health of these firms can get dicey very quickly, given the amount of capital investment it requires to run them.
